NSCLC STAGE IV

This study tests a cancer peptide vaccine designed to prevent or delay resistance in people with advanced ALK-positive lung cancer who are already on targeted therapy. About 12 participants will receive the vaccine alongside their current medication. The main goals are to check s…

This study tests a new drug called M701 in people with advanced lung cancer that has spread to the lining of the lungs, causing fluid buildup (malignant pleural effusion). The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are…

This study tests whether adding a precise, high-dose radiation treatment to the liver (called L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either stand…

This study tests whether adding pirfenidone to the immunotherapy drug atezolizumab can improve tumor shrinkage and reduce treatment resistance in people with stage 4 or recurrent non-small cell lung cancer. About 25 adults who have already tried at least one prior treatment will …

This study tests a new drug called repotrectinib in 30 frail or elderly patients with advanced lung cancer that has a specific genetic change (ROS1). The goal is to see if the drug can shrink tumors and be well-tolerated in this group, who are often left out of other trials. Part…

This study is observing how well the immunotherapy drug atezolizumab works as the first treatment for people with stage IV non-small cell lung cancer that has high PD-L1 levels and no targetable gene changes. About 150 participants will be followed in regular clinic settings to s…

This phase 3 trial tests whether adding an experimental drug (N-803) to standard chemotherapy (docetaxel) can help people with advanced non-small cell lung cancer whose disease has stopped responding to immunotherapy. About 507 participants will be randomly assigned to receive ei…

This study tests whether continuing the immunotherapy drug cemiplimab for up to a year can help people with stage IV non-small cell lung cancer that has spread to only a few spots (oligometastatic). After initial treatment with cemiplimab plus chemotherapy and targeted radiation …

This study tests whether adding a hormone therapy (leuprorelin) to an immunotherapy (sintilimab) can help control advanced lung cancer in men aged 60 or older. The hormone therapy may rejuvenate the immune system to make the immunotherapy work better. The trial will measure tumor…

This study tests a combination of two drugs, sacituzumab tirumotecan and furmonertinib, in 25 adults with advanced non-squamous non-small cell lung cancer that has an EGFR gene mutation and has worsened after standard treatments. The goal is to see if the combo can shrink tumors …